Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry

Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry

Background: Ibrutinib is widely known as an effective and well-tolerated therapeutical choice of the chronic lymphocytic leukaemia (CLL). However, acquired resistance may occur during the treatment, causing relapse. Early detection of ibrutinib resistance is an important issue, therefore we aimed to...

Full description

Bibliographic Details
Main Authors: Ferenc Takács, Lili Kotmayer, Ágnes Czeti, Gábor Szalóki, Tamás László, Gábor Mikala, Ágnes Márk, András Masszi, Péter Farkas, Márk Plander, Júlia Weisinger, Judit Demeter, Sándor Fekete, László Szerafin, Beáta Margit Deák, Erika Szaleczky, Adrienn Sulák, Zita Borbényi, Gábor Barna
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Pathology and Oncology Research
Subjects:
flow cytometry
targeted therapy
drug resistance
chronic lymphocytic leukaemia
ibrutinib
Online Access:https://www.por-journal.com/articles/10.3389/pore.2022.1610659/full

Internet

https://www.por-journal.com/articles/10.3389/pore.2022.1610659/full

Similar Items